Sonoma Pharmaceuticals Inc., of Petaluma, Calif., said it is now compliant with the minimum bid price requirement for continued listing on Nasdaq and is no longer subject to delisting at this time. To achieve compliance, the company implemented a 1-for-9 reverse stock split last month.

Horizon Therapeutics plc, of Dublin, said Horizon Pharma U.S. Inc., its wholly owned subsidiary, priced its offering of $600 million aggregate principal amount of 5.5% senior notes due 2027. 

A False Claims Act suit was unsealed alleging that Johnson & Johnson fraudulently obtained a patent to block generic competition for prostate cancer drug Zytiga (abiraterone acetate), a drug that costs roughly $9,000 per month and generates about $2.4 billion in annual revenue for New Brunswick, N.J.-based J&J, according to law firm Herrera Purdy LLP. 

Schrodinger Inc., of New York, said it received a preclinical milestone payment from Sanofi SA, of Paris, in a drug discovery program advancing as part of a multiyear, multitarget collaboration.

Hemostemix Inc., of Calgary, Alberta, said it will not proceed with its nonbrokered private placement of up to $6 million in secured convertible debentures and will not have a second close of its nonbrokered private placement of up to $1 million in secured convertible debentures, which previously raised gross proceeds of $525,000. The company said it continues to pursue efforts to raise capital to fund operations and an ongoing phase II trial.

Ideaya Biosciences Inc., of South San Francisco, appointed Paul A. Stone chief financial officer, Andres Briseno, vice president, finance and Mick O'Quigley vice president, development operations.